| Title: |
Real-world Effectiveness of Molnupiravir and Nirmatrelvir/Ritonavir as Treatments for COVID-19 in Patients at High Risk |
| Authors: |
Paraskevis, Dimitrios; Gkova, Maria; Mellou, Kassiani; Gerolymatos, Gerasimos; Psalida, Naya; Gkolfinopoulou, Kassiani; Kostaki, Evangelia-Georgia; Loukides, Stylianos; Kotanidou, Anastasia; Skoutelis, Athanasios; Thiraios, Eleftherios; Saroglou, Georgios; Zografopoulos, Dimitrios; Filippou, Dimitrios; Mossialos, Elias; Zaoutis, Theoklis; Gaga, Mina; Tsiodras, Sotirios; Antoniadou, Anastasia |
| Contributors: |
National Public Health Organization, Greece |
| Source: |
The Journal of Infectious Diseases ; volume 228, issue 12, page 1667-1674 ; ISSN 0022-1899 1537-6613 |
| Publisher Information: |
Oxford University Press (OUP) |
| Publication Year: |
2023 |
| Description: |
Background Using a retrospective cohort study design, we aimed to evaluate the effectiveness of molnupiravir and nirmatrelvir/ritonavir in patients with SARS-CoV-2 who were highly vulnerable. Methods The impact of each drug was determined via comparisons with age-matched control groups of patients positive for SARS-CoV-2 who did not receive oral antiviral therapy. Results Administration of molnupiravir significantly reduced the risk of hospitalization (odds ratio [OR], 0.40; P < .001) and death (OR, 0.31; P < .001) among these patients based on data adjusted for age, previous SARS-CoV-2 infection, vaccination status, and time elapsed since the most recent vaccination. The reductions in risk were most profound among elderly patients (≥75 years old) and among those with high levels of drug adherence. Administration of nirmatrelvir/ritonavir also resulted in significant reductions in the risk of hospitalization (OR, 0.31; P < .001) and death (OR, 0.28; P < .001). Similar to molnupiravir, the impact of nirmatrelvir/ritonavir was more substantial among elderly patients and in those with high levels of drug adherence. Conclusions Collectively, these real-world findings suggest that although the risks of hospitalization and death due to COVID-19 have been reduced, antivirals can provide additional benefits to members of highly vulnerable patient populations. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| DOI: |
10.1093/infdis/jiad324 |
| DOI: |
10.1093/infdis/jiad324/51401782/jiad324.pdf |
| Availability: |
https://doi.org/10.1093/infdis/jiad324; https://academic.oup.com/jid/advance-article-pdf/doi/10.1093/infdis/jiad324/51401782/jiad324.pdf; https://academic.oup.com/jid/article-pdf/228/12/1667/54717230/jiad324.pdf |
| Rights: |
https://creativecommons.org/licenses/by/4.0/ |
| Accession Number: |
edsbas.8BB5DC28 |
| Database: |
BASE |